Open access
Oct 2026
Search for prognostic factors when prescribing immunotherapy in the second line of treatment for metastatic gastric cancer
The results obtained leave a reasonable assumption that a group of patients on the 1st line had PFS > 8 months and a normal baseline LDH level, and they had real benefits from ICI therapy with the 2nd line therapy for metastatic gastric cancer.
N. N. Semenov, M. Fedyanin, L. Zhukova
· Malignant tumours · 0 citations